Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740164 | 1.00 | MEN1 (0.43) | MEN1AHRKMT2AP4HTMSMN1; SMN2 | |
| SCHEMBL30836800 | 0.88 | MEN1 (0.43) | MEN1AHRKMT2ASMN1; SMN2MAPT | |
| SCHEMBL31108231 | 0.83 | KDM4E (0.38) | MEN1KMT2ASMN1; SMN2MAPTPOLB | |
| SCHEMBL20293687 | 0.83 | PDCD1 (0.54) | PDCD1CD274 | |
| SCHEMBL29779288 | 0.83 | PDCD1 (0.54) | PDCD1CD274 | |
| SCHEMBL20293724 | 0.81 | PDCD1 (0.51) | PDCD1CD274 | |
| SCHEMBL27080495 | 0.81 | PDCD1 (0.42) | MEN1AHRKMT2APOLBPDCD1 | |
| SCHEMBL23685216 | 0.81 | MAPK1 (0.55) | MEN1AHRKMT2AP4HTMSMN1; SMN2 | |
| SCHEMBL30257716 | 0.81 | MAPK1 (0.55) | MEN1AHRKMT2AP4HTMSMN1; SMN2 | |
| SCHEMBL31108280 | 0.80 | PDCD1 (0.47) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3558985-B1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119221-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119221-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
| US-20220194931-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
| US-10308644-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
| US-20180179197-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MEN1 1546/4885AHR 199/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.